Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of <i>TP53</i> mutational status.
Aldoss, Ibrahim; Pham, Anh; Li, Sierra Min; Gendzekhadze, Ketevan; Afkhami, Michelle; Telatar, Milhan; Hong, Hao; Padeganeh, Abbas; Bedell, Victoria; Cao, Thai; Khaled, Samer K; Malki, Monzr M Al; Salhotra, Amandeep; Ali, Haris; Aribi, Ahmed; Palmer, Joycelynne; Aoun, Patricia; Spielberger, Ricardo; Stein, Anthony S; Snyder, David; O'Donnell, Margaret R; Murata-Collins, Joyce; Senitzer, David; Weisenburger, Dennis; Forman, Stephen J; Pullarkat, Vinod; Marcucci, Guido; Pillai, Raju; Nakamura, Ryotaro.
; 102(12): 2030-2038, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28971906
Changing the treatment paradigm in myelodysplastic syndromes.
Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?
Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.
Current state of prognostication and risk stratification in myelodysplastic syndromes.
Myelodysplastic syndromes: Contemporary review and how we treat.
Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.
Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes.
Clinical and genetic predictors of prognosis in myelodysplastic syndromes.